ARTICLE | Company News

Valeant Pharmaceuticals, Mylan deal

February 13, 2012 8:00 AM UTC

Valeant divested generic versions of dermatology drugs BenzaClin clindamycin/benzoyl peroxide gel and Efudex fluorouracil cream to Mylan. The deal includes an ANDA for generic BenzaClin to treat acne and a license to manufacture and market an authorized generic of Efudex to treat actinic keratosis (AK) and superficial basal cell carcinoma. Valeant was required under a consent order from the Federal Trade Commission to divest the two products as part of its December acquisition of the Dermik dermatology unit of Sanofi (Euronext:SAN; NYSE:SNY, Paris, France). Details were not disclosed (see BioCentury, Jan. 2). ...